Lifitegrast Ophthalmic Solution Market: Overview
Lifitegrast, available under the trade
name Xiidra is the first U.S. FDA approved drug for treating the signs
and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as
dry eye disease is a chronic disorder, which is related to lack of tears
in order to maintain sufficient moisture in the eye. The condition is
either due to less production of tears or quick drying of tears in the
eye. Across the world, over 300 million people are reckoned to be
suffering from this condition.
Dry eye disease (DED) involves pain,
redness, light sensitivity, blurred vision, burning, and inflammation.
The primary factors for DED include dry environment, allergy, sun
exposure, smoke exposure, heat or chemical burns, aging, previous
surgery, contact lenses or infection. At present, there are several
treatment approaches available for managing dry eye syndrome, which
includes lubricant treatments, anti-inflammatory treatments, autologous
serum eye drops, and surgery.
The report presents a comprehensive
evaluation of the Xiidra market. This includes analyzing the historic
and current performance of the market for future estimates of the growth
trajectory of the market.
The assessment of the vendor landscape
makes for an interesting read as analysts have not only mentioned the
top players in the market but have also profiled them in detail. Vital
aspects such as business overview, business strategies, product
portfolio, financial standing, and recent developments have been taken
into consideration to assess the performance of the top players during
the forecast period. Using SWOT analysis, readers are provided a clear
understanding of the indicators of strengths, weakness, opportunities,
and threats of each of the company.
Lifitegrast Ophthalmic Solution Market: Drivers and Restraints
The rising prevalence of dry eye syndrome
(DES) across the world is the primary factor attributable to the growth
of the Lifitegrast ophthalmic solution market. Diabetes, rheumatoid
arthritis, thyroid disorders, lupus, and vitamin A deficiency are some
of the underpinning factors that are accounted for the increasing
prevalence of dry eye syndrome.
Being the first to receive FDA approval
for treating the sign as well as symptoms of DES, the Xiidra market is
expected to rise exponentially in the near future. The increasing demand
for advanced treatment options for DES is expected to be favorable for
the growth of the Lifitegrast ophthalmic solution market. The rising
geriatric population across the world that is prone to several health
conditions also accounts for the high prevalence of dry eye syndrome as a
secondary condition.
Dry eye syndrome was earlier not
considered seriously as it did not affect everyday functioning. However,
the rising awareness about the ill-effects of dry eye syndrome is
expected to favor the market’s growth exponentially. Moreover,
increasing awareness about the management of this condition is further
assisting the market’s growth.
In present times, high level of pollution
and rising industrialization is often an underlying factor for the
rising prevalence of dry eye disease. However, with rising awareness
about the diagnosis and treatment of the disorder will augment the
growth of Xiidra market.
Despite the increasing prevalence of dry
eye disease, the underdiagnosis of the condition is restraining the
market’s growth. Moreover, the trend among patients to render
self-medication remains a major restraint for the growth of the Xiidra
market.
Major Companies Mentioned in Report
Some of the key players in the global
market for dry eye syndrome include Novartis AG, Allergan Inc., Cellzome
GmbH, NicOx SA, Bridge Pharma Inc., and Santen Pharmaceutical Co. Ltd.
No comments:
Post a Comment